UA101315C2 - СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА КАК ИНГИБИТОРЫ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА - Google Patents
СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА КАК ИНГИБИТОРЫ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКАInfo
- Publication number
- UA101315C2 UA101315C2 UAA200911451A UAA200911451A UA101315C2 UA 101315 C2 UA101315 C2 UA 101315C2 UA A200911451 A UAA200911451 A UA A200911451A UA A200911451 A UAA200911451 A UA A200911451A UA 101315 C2 UA101315 C2 UA 101315C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heading
- compounds
- cancer
- treatment
- pi3k
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- WDHAAJIGSXNPFO-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-7-one Chemical class N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91116007P | 2007-04-11 | 2007-04-11 | |
| PCT/US2008/004807 WO2008127712A1 (en) | 2007-04-11 | 2008-04-11 | Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA101315C2 true UA101315C2 (ru) | 2013-03-25 |
Family
ID=39642739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200911451A UA101315C2 (ru) | 2007-04-11 | 2008-04-11 | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА КАК ИНГИБИТОРЫ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20100209340A1 (show.php) |
| EP (1) | EP2142544B8 (show.php) |
| JP (1) | JP2010523681A (show.php) |
| KR (1) | KR20090130104A (show.php) |
| CN (1) | CN101711249A (show.php) |
| AU (1) | AU2008239596B2 (show.php) |
| BR (1) | BRPI0810175A2 (show.php) |
| CA (1) | CA2683820A1 (show.php) |
| CO (1) | CO6241119A2 (show.php) |
| CR (1) | CR11098A (show.php) |
| DO (1) | DOP2009000242A (show.php) |
| EA (1) | EA018964B1 (show.php) |
| EC (1) | ECSP099722A (show.php) |
| ES (1) | ES2425068T3 (show.php) |
| IL (1) | IL201209A0 (show.php) |
| MA (1) | MA31336B1 (show.php) |
| MX (1) | MX2009010815A (show.php) |
| MY (1) | MY150747A (show.php) |
| NI (1) | NI200900183A (show.php) |
| NZ (1) | NZ579945A (show.php) |
| SV (1) | SV2009003389A (show.php) |
| TN (1) | TN2009000389A1 (show.php) |
| UA (1) | UA101315C2 (show.php) |
| WO (1) | WO2008127712A1 (show.php) |
| ZA (1) | ZA200906648B (show.php) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767687B2 (en) * | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| UA116188C2 (uk) * | 2005-10-07 | 2018-02-26 | Екселіксіс, Інк. | Інгібітори фосфатидилінозит-3-кінази і способи їх застосування |
| EA016945B1 (ru) * | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
| DK2074122T5 (da) | 2006-09-15 | 2014-03-17 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer |
| RS52939B (sr) | 2007-04-10 | 2014-02-28 | Exelixis Inc. | Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa |
| EP2142543B8 (en) * | 2007-04-11 | 2013-07-03 | Exelixis, Inc. | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
| US8101622B2 (en) * | 2008-09-30 | 2012-01-24 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
| US20120040950A1 (en) * | 2009-12-22 | 2012-02-16 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| AR080151A1 (es) | 2010-02-09 | 2012-03-14 | Exelixis Inc | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia |
| ES2693257T3 (es) | 2010-09-14 | 2018-12-10 | Exelixis, Inc. | Inhibidores de PI3K-delta y métodos para su uso y fabricación |
| WO2013056067A1 (en) * | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
| HK1201480A1 (en) | 2011-11-01 | 2015-09-04 | Exelixis, Inc. | N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide as phosphatidylinositol 3-kinase inhibitor for the treatment of lymphoproliferative malignancies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2937284A (en) * | 1958-05-01 | 1960-05-17 | Burroughs Wellcome Co | 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method |
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| ATE373659T1 (de) * | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
| EA016945B1 (ru) * | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα |
| AU2006302148B2 (en) * | 2005-10-07 | 2012-12-06 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kalpha |
| AU2007284562B2 (en) * | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
| DK2074122T5 (da) * | 2006-09-15 | 2014-03-17 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer |
-
2008
- 2008-04-11 EP EP08742864.5A patent/EP2142544B8/en active Active
- 2008-04-11 MY MYPI20094194 patent/MY150747A/en unknown
- 2008-04-11 US US12/595,233 patent/US20100209340A1/en not_active Abandoned
- 2008-04-11 MX MX2009010815A patent/MX2009010815A/es active IP Right Grant
- 2008-04-11 EA EA200970936A patent/EA018964B1/ru not_active IP Right Cessation
- 2008-04-11 NZ NZ579945A patent/NZ579945A/en not_active IP Right Cessation
- 2008-04-11 ES ES08742864T patent/ES2425068T3/es active Active
- 2008-04-11 BR BRPI0810175-2A2A patent/BRPI0810175A2/pt not_active IP Right Cessation
- 2008-04-11 CA CA002683820A patent/CA2683820A1/en not_active Abandoned
- 2008-04-11 KR KR1020097023146A patent/KR20090130104A/ko not_active Ceased
- 2008-04-11 UA UAA200911451A patent/UA101315C2/ru unknown
- 2008-04-11 CN CN200880018758A patent/CN101711249A/zh active Pending
- 2008-04-11 AU AU2008239596A patent/AU2008239596B2/en not_active Ceased
- 2008-04-11 WO PCT/US2008/004807 patent/WO2008127712A1/en not_active Ceased
- 2008-04-11 JP JP2010503085A patent/JP2010523681A/ja active Pending
-
2009
- 2009-09-23 ZA ZA200906648A patent/ZA200906648B/xx unknown
- 2009-09-24 TN TNP2009000389A patent/TN2009000389A1/fr unknown
- 2009-09-29 IL IL201209A patent/IL201209A0/en unknown
- 2009-10-09 SV SV2009003389A patent/SV2009003389A/es not_active Application Discontinuation
- 2009-10-09 NI NI200900183A patent/NI200900183A/es unknown
- 2009-10-09 DO DO2009000242A patent/DOP2009000242A/es unknown
- 2009-10-30 MA MA32314A patent/MA31336B1/fr unknown
- 2009-11-09 CR CR11098A patent/CR11098A/es unknown
- 2009-11-09 CO CO09126919A patent/CO6241119A2/es not_active Application Discontinuation
- 2009-11-09 EC EC2009009722A patent/ECSP099722A/es unknown
-
2013
- 2013-01-03 US US13/694,772 patent/US20130343988A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2142544B8 (en) | 2013-07-03 |
| ES2425068T3 (es) | 2013-10-11 |
| SV2009003389A (es) | 2010-04-27 |
| CA2683820A1 (en) | 2008-10-23 |
| EP2142544A1 (en) | 2010-01-13 |
| JP2010523681A (ja) | 2010-07-15 |
| EP2142544B1 (en) | 2013-05-22 |
| AU2008239596A1 (en) | 2008-10-23 |
| TN2009000389A1 (en) | 2010-12-31 |
| CR11098A (es) | 2010-01-27 |
| ECSP099722A (es) | 2009-12-28 |
| NI200900183A (es) | 2010-10-05 |
| US20130343988A1 (en) | 2013-12-26 |
| CO6241119A2 (es) | 2011-01-20 |
| MY150747A (en) | 2014-02-28 |
| WO2008127712A1 (en) | 2008-10-23 |
| CN101711249A (zh) | 2010-05-19 |
| EA200970936A1 (ru) | 2010-02-26 |
| US20100209340A1 (en) | 2010-08-19 |
| BRPI0810175A2 (pt) | 2014-12-30 |
| EA018964B1 (ru) | 2013-12-30 |
| KR20090130104A (ko) | 2009-12-17 |
| NZ579945A (en) | 2012-05-25 |
| HK1139941A1 (en) | 2010-09-30 |
| MA31336B1 (fr) | 2010-04-01 |
| MX2009010815A (es) | 2009-10-29 |
| DOP2009000242A (es) | 2010-04-30 |
| IL201209A0 (en) | 2010-05-31 |
| AU2008239596B2 (en) | 2013-08-15 |
| ZA200906648B (en) | 2010-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA101315C2 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА КАК ИНГИБИТОРЫ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| GEP20247679B (en) | Bicyclic heterocycles as fgfr inhibitors | |
| TN2009000142A1 (en) | Bicyclic triazoles as protein kinase modulators | |
| WO2012007345A3 (en) | Substituted imidazo[1,2-a]pyrimidines and -pyridines | |
| WO2005117867A3 (en) | Monocyclic heterocycles as kinase inhibitors | |
| WO2011080568A8 (en) | Novel pyrimidine compounds as mtor and pi3k inhibitors | |
| JO3181B1 (ar) | مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود | |
| MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| MX2009004699A (es) | Compuestos de piridinona. | |
| PH12012502391A1 (en) | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | |
| MX2009006535A (es) | Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina. | |
| MX358682B (es) | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). | |
| MX2009012066A (es) | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. | |
| MX2010008198A (es) | Inhibidores de cinasa de pirrolopirazina. | |
| MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
| PH12012502410A1 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| UA104731C2 (ru) | Ингибиторы р38 мар-киназ | |
| MX2020009397A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| MX2012001419A (es) | Compuestos biciclicos novedosos de urea. | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| MX2009004623A (es) | Imidazopiridazinas como inhibidores de la lipido cinasa pi3k. | |
| WO2011101069A3 (en) | 1, 8 -naphthyridines as kinase inhibitors | |
| WO2008049855A3 (en) | 7-azaindole derivatives as c-met kinase inhibitors | |
| WO2010021934A3 (en) | Azaindole inhibitors of iap | |
| MX2012002327A (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. |